IL139965A0 - Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway and inhibitors of lipid metabolism - Google Patents

Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway and inhibitors of lipid metabolism

Info

Publication number
IL139965A0
IL139965A0 IL13996599A IL13996599A IL139965A0 IL 139965 A0 IL139965 A0 IL 139965A0 IL 13996599 A IL13996599 A IL 13996599A IL 13996599 A IL13996599 A IL 13996599A IL 139965 A0 IL139965 A0 IL 139965A0
Authority
IL
Israel
Prior art keywords
methylerythrose
inhibitors
inhibit
active compounds
lipid metabolism
Prior art date
Application number
IL13996599A
Other languages
English (en)
Original Assignee
Jomaa Hassan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19828097A external-priority patent/DE19828097A1/de
Application filed by Jomaa Hassan filed Critical Jomaa Hassan
Publication of IL139965A0 publication Critical patent/IL139965A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
IL13996599A 1998-06-24 1999-06-23 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway and inhibitors of lipid metabolism IL139965A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19828097A DE19828097A1 (de) 1998-06-24 1998-06-24 Kombinationspräparat von Aminohydrocarbylphosphonsäurederivaten und Hemmern des Fettstoffwechsels
DE19843279 1998-09-22
PCT/EP1999/004360 WO1999066875A2 (de) 1998-06-24 1999-06-23 Kombinationspräparat von antiinfektiös wirkenden verbindungen, die den 2-c-methylerythrose-4-stoffwechselweg hemmen, und hemmern des fettstoffwechsels

Publications (1)

Publication Number Publication Date
IL139965A0 true IL139965A0 (en) 2002-02-10

Family

ID=26047010

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13996599A IL139965A0 (en) 1998-06-24 1999-06-23 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway and inhibitors of lipid metabolism

Country Status (10)

Country Link
EP (1) EP1100510A2 (de)
JP (1) JP2002518418A (de)
CN (1) CN1348374A (de)
AU (1) AU752714B2 (de)
CA (1) CA2334645A1 (de)
IL (1) IL139965A0 (de)
PL (1) PL345513A1 (de)
SK (1) SK19612000A3 (de)
TR (1) TR200003783T2 (de)
WO (1) WO1999066875A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053071A1 (fr) 1998-04-14 1999-10-21 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composes isoprenoides au moyen de micro-organismes et procede de detection de composes ayant une action antibacterienne ou herbicide
EP3387907B1 (de) * 2014-02-23 2021-10-20 FMC Corporation Verwendung von 3-isoxazolidonen als selektive herbizide mittel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS6064991A (ja) * 1983-09-17 1985-04-13 Fujisawa Pharmaceut Co Ltd セファレキシン・ホスミドマイシン塩およびその製造法
US4846872A (en) * 1986-08-11 1989-07-11 Fujisawa Pharmaceutical Co., Ltd. Herbicide
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
EP0537008B1 (de) * 1991-10-11 1995-10-25 E.R. SQUIBB & SONS, INC. Verwendung von Biphosphonaten zur Herstellung eines Arzneimittels zur Blockierung neoplastischer Zelltransformationen die durch Ras-Oncogene verursacht werden

Also Published As

Publication number Publication date
CA2334645A1 (en) 1999-12-29
AU752714B2 (en) 2002-09-26
AU4615599A (en) 2000-01-10
PL345513A1 (en) 2001-12-17
CN1348374A (zh) 2002-05-08
WO1999066875A2 (de) 1999-12-29
TR200003783T2 (tr) 2001-06-21
WO1999066875A3 (de) 2000-09-14
SK19612000A3 (sk) 2001-08-06
JP2002518418A (ja) 2002-06-25
EP1100510A2 (de) 2001-05-23

Similar Documents

Publication Publication Date Title
HUP0103707A3 (en) Formulation of stable oxalyplatinum solution
HUP0103464A3 (en) Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
HK1035194A1 (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient
HUP0003705A3 (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
IL139321A0 (en) Methods and compositions for modulating lipid metabolism
IL137928A0 (en) Dietary control of arachidonic acid metabolism
IL123232A0 (en) Medicament for inhibiting glucose metabolism deterioration
NO20011459D0 (no) Gener i biosyntesereaksjonsveien til 1-desoksy-D-xylulose
AU3445699A (en) Microbial preparation of substances from aromatic metabolism/iii
IL140667A0 (en) Compositions containing at least one active substance having an influence on the levels of lipids in the blood
HK1043125A1 (zh) 作為治療活性化合物的磺酰基噁唑胺
AU2002328402A1 (en) Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
IL139965A0 (en) Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway and inhibitors of lipid metabolism
HUP9802716A3 (en) Pharmaceutical composition of analgesic activity
AU7533194A (en) Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism
AU5682900A (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments
AU4329797A (en) Lipid metabolic pathway compositions and therapeutic and diagnostic uses therefor
AU6104498A (en) Active composition for combating the effects of the cold and cosmetic product containing this composition
TW394074U (en) Improved structure of in-line roller-skates
TW355395U (en) Secure structure of leggings for in-line skates
TW410558U (en) Improved structure of shoelace
HUP0102705A2 (hu) alfa-Aminosav-fenil-észterszármazékok és alkalmazásuk, valamint, e vegyületeket tartalmazó gyógyászati készítmények
GB9805675D0 (en) Preparation of solid lipid compositions
TW356820U (en) Improved structure for tape seat of double sides tape stand